Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin

@inproceedings{Chen2013TargetedTF,
  title={Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin},
  author={Xueyan Chen and Lorinda A. Soma and Jonathan R. Fromm},
  booktitle={OncoTargets and therapy},
  year={2013}
}
Despite the relative success of chemotherapy for Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), novel therapeutic agents are needed for refractory or relapsed patients. Targeted immunotherapy has emerged as a novel treatment option for these patients. Although unconjugated anti-cluster of differentiation (CD)30 antibodies showed minimal antitumor activity in early clinical trials, development of antibody-drug conjugates (ADCs) appears promising. Brentuximab vedotin is… CONTINUE READING
13 Citations
92 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 92 references

Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes

  • L Lamant, A de Reyniès, MM Duplantier
  • Blood
  • 2007
Highly Influential
12 Excerpts

Similar Papers

Loading similar papers…